OTCPK:AXIM

Stock Analysis Report

Executive Summary

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • AXIM Biotechnologies has significant price volatility in the past 3 months.
  • AXIM Biotechnologies is not covered by any analysts.

Similar Companies

Share Price & News

How has AXIM Biotechnologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-16.4%

OTCPK:AXIM

-0.9%

US Pharmaceuticals

-1.2%

US Market


1 Year Return

-70.8%

OTCPK:AXIM

3.7%

US Pharmaceuticals

3.4%

US Market

AXIM underperformed the Pharmaceuticals industry which returned 3.7% over the past year.

AXIM underperformed the Market in United States of America which returned 3.4% over the past year.


Share holder returns

AXIMIndustryMarket
7 Day-16.4%-0.9%-1.2%
30 Day-2.4%-4.0%1.2%
90 Day-42.1%0.8%1.7%
1 Year-70.8%-70.8%6.2%3.7%5.7%3.4%
3 Year163.9%163.9%7.8%0.2%45.0%35.5%
5 Year-92.2%-92.2%25.6%12.1%59.3%41.6%

Price Volatility Vs. Market

How volatile is AXIM Biotechnologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AXIM Biotechnologies undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether AXIM Biotechnologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AXIM Biotechnologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of AXIM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AXIM Biotechnologies regulatory filings here.
  • Explore potentially undervalued companies in the pharmaceuticals & biotech industry.

Future Growth

How is AXIM Biotechnologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.2%

Forecasted Pharmaceuticals industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AXIM Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AXIM Biotechnologies performed over the past 5 years?

-23.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

AXIM Biotechnologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare AXIM Biotechnologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare AXIM Biotechnologies's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if AXIM Biotechnologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if AXIM Biotechnologies has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if AXIM Biotechnologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is AXIM Biotechnologies's financial position?


Financial Position Analysis

AXIM Biotechnologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

AXIM Biotechnologies's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

AXIM Biotechnologies has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if AXIM Biotechnologies's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

AXIM Biotechnologies has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

AXIM Biotechnologies has less than a year of cash runway based on current free cash flow.

AXIM Biotechnologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 51% each year.


Next Steps

Dividend

What is AXIM Biotechnologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate AXIM Biotechnologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate AXIM Biotechnologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as AXIM Biotechnologies has not reported any payouts.

Unable to verify if AXIM Biotechnologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as AXIM Biotechnologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of AXIM Biotechnologies's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

John Huemoeller (64yo)

0.5yrs

Tenure

US$45,000

Compensation

Mr. John W. Huemoeller, II, has been Chief Executive Officer of AXIM Biotechnologies, Inc. since January 2, 2019. Mr. Huemoeller serves as the Chief Executive Officer of Novas. Mr. Huemoeller served as the ...


Management Age and Tenure

1.8yrs

Average Tenure

56yo

Average Age

The average tenure for the AXIM Biotechnologies management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.3yrs

Average Tenure

64yo

Average Age

The tenure for the AXIM Biotechnologies board of directors is about average.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Robert Malasek (51yo)

    CFO & Secretary

    • Tenure: 3.1yrs
    • Compensation: $247.00k
  • John Huemoeller (64yo)

    CEO & Director

    • Tenure: 0.5yrs
    • Compensation: $45.00k
  • George Anastassov (56yo)

    Founder & Chairman

    • Compensation: $595.00k
  • Philip Van Damme (66yo)

    Chief Medical Officer & Director

    • Tenure: 0.5yrs
    • Compensation: $45.00k
  • Lekhram Changoer (52yo)

    CTO & Director

    • Tenure: 5.2yrs
    • Compensation: $475.00k

Board Members

  • Timothy Scott (66yo)

    Director

    • Compensation: $45.00k
  • Robert Ritch

    Member of Advisory Board

    • Tenure: 2.6yrs
  • Ilya Reznik

    Member of Advisory Board

    • Tenure: 2.6yrs
  • John Huemoeller (64yo)

    CEO & Director

    • Compensation: $45.00k
  • George Anastassov (56yo)

    Founder & Chairman

    • Compensation: $595.00k
  • Renger Witkamp

    Member of Advisory Board

    • Tenure: 4.8yrs
  • John Zajicek

    Member of Advisory Board

    • Tenure: 4.8yrs
  • Philip Van Damme (66yo)

    Chief Medical Officer & Director

    • Compensation: $45.00k
  • Jacques Meis

    Member of Advisory Board

    • Tenure: 4.3yrs
  • Lekhram Changoer (52yo)

    CTO & Director

    • Compensation: $475.00k

Company Information

AXIM Biotechnologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AXIM Biotechnologies, Inc.
  • Ticker: AXIM
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$45.863m
  • Shares outstanding: 61.84m
  • Website: Click here

Number of Employees


Location

  • AXIM Biotechnologies, Inc.
  • 45 Rockefeller Plaza
  • 20th Floor
  • New York
  • New York
  • 10111
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXIMOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2013

Biography

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of ca ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/21 01:06
End of Day Share Price2019/07/19 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.